Adlai Nortye Partners With Lilly, Merck KGaA on AN4035 — Cetuximab Cancer Trial

Adlai Nortye today entered clinical trial collaboration and supply agreements with Eli Lilly and Germany's Merck to evaluate AN4035 with cetuximab. The ongoing global Phase I trial tests AN4035 alone or with cetuximab in patients with CEACAM5-enriched, RAS-addicted solid tumors. Lilly will supply cetuximab at no cost to US trial sites. * Merck will provide cetuximab free of charge to trial sites in Australia and China. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nortye Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-109576), on October 15, 2026, and is solely responsible for the information contained therein. (C)